n-(4-Fluorobenzyl)-2-(4-isobutoxyphenyl)-n-{1-(3-piperidin-1-yl-propyl)piperidin-4-yl}-acetamide, dihydrochloride

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: n-(4-Fluorobenzyl)-2-(4-isobutoxyphenyl)-n-{1-(3-piperidin-1-yl-propyl)piperidin-4-yl}-acetamide, dihydrochloride
• 英文别名: N-[(4-fluorophenyl)methyl]-2-[4-(2-methylpropoxy)phenyl]-N-[1-(3-piperidin-1-ylpropyl)piperidin-4-yl]acetamide;dihydrochloride
• 化学式: C32H48Cl2FN3O2
• 分子量: 596.6
• InChiKey: OGMAIHYCSDBUPB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.62
• 重原子数：
  40
• 可旋转键数：
  12
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  36
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  N-(4-fluorobenzyl)-N-(piperidin-4-yl)-2-(4-isobutyloxyphenyl)acetamide 、 2-(2-氯乙氧基)四氢-2H-吡喃 在 n-(4-Fluorobenzyl)-2-(4-isobutoxyphenyl)-n-{1-(3-piperidin-1-yl-propyl)piperidin-4-yl}-acetamide, dihydrochloride 、 silica gel 、 甲醇 、 二氯甲烷 作用下， 以afforded the title compound (96 mg, 40%)的产率得到n-(4-Fluorobenzyl)-2-(4-isobutoxyphenyl)-n-{1-(3-piperidin-1-yl-propyl)piperidin-4-yl}-acetamide, dihydrochloride
  参考文献：
  名称：

  N-substituted piperidine derivatives as serotonin receptor agents

  摘要：

  本文披露了一种公式I的化合物，或其药物可接受的盐、酰胺、酯或前药。还披露了一种抑制单胺受体活性的方法，包括将单胺受体或含有单胺受体的系统与一种或多种公式I的化合物的有效量接触。还披露了一种抑制单胺受体激活的方法，包括将单胺受体或含有单胺受体的系统与一种或多种公式I的化合物的有效量接触。此外，还披露了使用公式I的化合物治疗精神疾病的方法。

  公开号：

  US20040106600A1
• 作为试剂：
  描述：

  N-(4-fluorobenzyl)-N-(piperidin-4-yl)-2-(4-isobutyloxyphenyl)acetamide 、 2-(2-氯乙氧基)四氢-2H-吡喃 在 n-(4-Fluorobenzyl)-2-(4-isobutoxyphenyl)-n-{1-(3-piperidin-1-yl-propyl)piperidin-4-yl}-acetamide, dihydrochloride 、 silica gel 、 甲醇 、 二氯甲烷 作用下， 以afforded the title compound (96 mg, 40%)的产率得到n-(4-Fluorobenzyl)-2-(4-isobutoxyphenyl)-n-{1-(3-piperidin-1-yl-propyl)piperidin-4-yl}-acetamide, dihydrochloride
  参考文献：
  名称：

  N-substituted piperidine derivatives as serotonin receptor agents

  摘要：

  本文披露了一种公式I的化合物，或其药物可接受的盐、酰胺、酯或前药。还披露了一种抑制单胺受体活性的方法，包括将单胺受体或含有单胺受体的系统与一种或多种公式I的化合物的有效量接触。还披露了一种抑制单胺受体激活的方法，包括将单胺受体或含有单胺受体的系统与一种或多种公式I的化合物的有效量接触。此外，还披露了使用公式I的化合物治疗精神疾病的方法。

  公开号：

  US20040106600A1

文献信息

• PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONERGIC AGENT AND METHODS OF USE THEREOF
  申请人：ALS Mountain Llc

  公开号：EP2983473A2

  公开（公告）日：2016-02-17
• NOVEL COMPOSITION FOR TREATING METABOLIC SYNDROME AND OTHER CONDITIONS
  申请人：Chen Chien-Hung

  公开号：US20120183600A1

  公开（公告）日：2012-07-19

  The invention relates to a composition that includes a first agent selected from the group consisting of an oxidative phosphorylation inhibitor, an ionophore, and an adenosine 5′-monophosphate-activated protein kinase (AMPK) activator; a second agent that possesses anti-inflammatory activity; and a third agent that possesses serotonin activity.
• [EN] PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONERGIC AGENT AND METHODS OF USE THEREOF<br/>[FR] COMPOSITION PHARMACEUTIQUE COMPRENANT UN ACTIVATEUR D'AMPK ET UN AGENT SÉROTONINERGIQUE ET PROCÉDÉS D'UTILISATION CORRESPONDANTS
  申请人：ALS MOUNTAIN LLC

  公开号：WO2014144130A2

  公开（公告）日：2014-09-18

  The present invention is based on the unexpected discovery that a combination of certain known drugs exhibits synergistic effects in treating metabolic syndrome and various other diseases. In particular, the invention comprises a pharmaceutical composition comprising: (1) a therapeutically effective quantity of a first agent that is an AMPK activator; and (2) a therapeutically effective quantity of a second agent that possesses or maintains serotonin activity. A preferred composition comprises metformin hydrochloride and melatonin. The invention further comprises methods for the use of these compositions for the treatment of metabolic syndrome, hyperproliferative diseases including cancer, and other diseases and conditions.
• N-substituted piperidine derivatives as serotonin receptor agents
  申请人：——

  公开号：US20040106600A1

  公开（公告）日：2004-06-03

  Disclosed herein are compounds of Formula I, 1 or a pharmaceutically acceptable salt, amide, ester, or prodrug thereof. Also disclosed are. methods of inhibiting an activity of a monoamine receptor comprising contacting the monoamine receptor or a system containing the monoamine receptor with an effective amount of one or more of the compounds of Formula I. Disclosed are also methods of inhibiting an activation of a monoamine receptor comprising contacting the monoamine receptor or a system containing the monoamine receptor with an effective amount of one or more of the compounds of Formula I. Furthermore, methods of treating psychotic disease using a compound of Formula I are disclosed.

  本文披露了一种公式I的化合物，或其药物可接受的盐、酰胺、酯或前药。还披露了一种抑制单胺受体活性的方法，包括将单胺受体或含有单胺受体的系统与一种或多种公式I的化合物的有效量接触。还披露了一种抑制单胺受体激活的方法，包括将单胺受体或含有单胺受体的系统与一种或多种公式I的化合物的有效量接触。此外，还披露了使用公式I的化合物治疗精神疾病的方法。